Teva Pharmaceutical Industries Ltd Given Consensus Recommendation of “Buy” by Analysts (NASDAQ:TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) has earned an average rating of “Buy” from the twenty-four analysts that are presently covering the company, AnalystRatingsNetwork reports. Ten equities research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $56.38.
A number of research firms have recently commented on TEVA. Analysts at Canaccord Genuity initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Friday, June 27th. They set a “hold” rating and a $55.70 price target on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, June 10th. They set a “market perform” rating on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, June 10th. They now have a $56.00 price target on the stock, up previously from $55.00.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 53.87 on Thursday. Teva Pharmaceutical Industries Ltd has a 1-year low of $36.26 and a 1-year high of $55.24. The stock’s 50-day moving average is $52.09 and its 200-day moving average is $48.54. The company has a market cap of $45.827 billion and a P/E ratio of 33.27.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last announced its earnings results on Thursday, May 1st. The company reported $1.22 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.22. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.11 million. During the same quarter in the prior year, the company posted $1.12 earnings per share. The company’s quarterly revenue was up 2.0% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $4.77 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.